Mahathir Bayena

Hormel Foods (NYSE:HRL) entered a definitive agreement to sell its Brazilian operations, which operate under the CERATTI brand, to Zanchetta Alimentos LTDA.

Satellos Bioscience (NASDAQ:MSLE) said the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.

Zentek (NASDAQ:ZTEK) said it has secured a pathway to sell its ZenGUARD enhanced air filtration media in the United States through an exclusive eight-year licensing agreement with Applied Silver.

Neurogene (NASDAQ:NGNE) reported updated Phase 1/2 clinical data showing 47 total developmental milestone gains across 10 participants treated with NGN-401 gene therapy for Rett syndrome.

Larimar Therapeutics (NASDAQ:LRMR) announced the submission of the first module of a rolling Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of Friedreich’s ataxia.

Zymeworks has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for $17 per share in cash.

Senator Cynthia Lummis said JPMorgan Chase CEO Jamie Dimon had misrepresented the Digital Asset Market Clarity Act by claiming it weakens anti-money laundering requirements for cryptocurrency businesses.

BCAL Diagnostics (ASX:BDX), an Australian healthcare company focused on early cancer detection, has secured firm commitments for a further A$4.9 million under its existing A$10 million convertible note facility, with the additional funds to be drawn down as required.

Changpeng Zhao (CZ) said Bitcoin (CRYPTO:BTC) and the broader cryptocurrency market have declined in 2026 because of a combination of geopolitical tensions, capital flowing into artificial intelligence and the sector's historical four-year market cycle.

The stablecoin market has contracted by approximately US$9.45 billion since May 8, reducing the amount of capital available to support cryptocurrency trading as investors continue withdrawing funds from digital asset markets.